share_log

Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30

Moomoo 24/7 ·  Apr 2 07:10

Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment